## |||||Page| |---|---|---|---|---| |Reference|and administrative||information|| |Chairman's|Letter|||| |Trustees'|Report|||3 —12| |Independent
Auditor's||Report||13-16| |Statement|of Financial|Activities||17| |Balance Sheet||||18| |Statement|of Cash Flows|||19| |Notes to the Financial||Statements||20- 34| |CHARITY NAME|Prostate Cancer|Prostate Cancer|Research|Research|Research|| |---|---|---|---|---|---|---| |CHARITY REGISTRATION NUMBER|1156027|||||| |REGISTERED OFFICE|Suite 2|||||| ||23-24 Great James Street|||||| ||London|||||| ||WC1N 3ES|||||| |PRINCIPAL OFFICE|Suite 2|||||| ||23-24 Great James Street|||||| ||London|||||| ||WC1N 3ES|||||| |TRUSTEES|Matthew
Ellis,|Chair of Trustees||||| ||Michele Hunter||(resigned|||11 July 2022)| ||Shaun Grady|||||| ||Ben Monro-Davies|||||| ||Mark Clark|||||| ||Suman Shirodkar|||MBBS,||PHD| ||Richard Collier|||||| ||Jonathan
Badger|||||| ||Ameet
Gill OBE|||||| ||Trevor Back|||||| ||Marcella Turner|||||| ||Louisa Fleur (appointed||||7|March 2023)| |EXECUTIVE DIRECTOR|Oliver Kemp|||||| |HONORARY TREASURER|Ceri Evans|||||| |BANKERS|Lloyds TSB|||||| ||Oxford Street|||||| ||London|||||| ||BX1 1LT|||||| ||HSBC|||||| ||39Tottenham|Court Road||||| ||London|||||| ||W1T 2AR|||||| ||Barclays Bank|pic||||| ||London Bridge|Branch||||| ||29 Borough
High Street|||||| ||London|||||| ||SE1 1LY|||||| |AUDITOR|Crowe U.K. LLP|||||| ||Aquis House|||||| ||49-51 Blagrave||Street|||| ||Reading|||||| ||RG1 1PL|||||| ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## |||||||||Total|Total| |---|---|---|---|---|---|---|---|---|---| ||||||Notes|Unrestricted|Restricted|funds|funds| |||||||funds|funds|2023|2022| |Income and endowments|||from:||||||| |Donations
and|legacies|||||1,822,685|1,164,925|2,987,610|2,660,859| |Investments||||||13,336||13,336|14,962| |Other income||||||1 854||1 854|| |Total income||||||~B3Z,BZ5|~~~|'+Q~QQ|2675821| |Expenditure
on:|||||||||| |Raising funds|||||5|1,049,831||1,049,831|879,060| |Charitable
activities|||||6|1 554435|850547|2404 982|1 743661| |Total expenditure||||||~Q~|~5L54Z|~4j~|2622 721| |Net movement|in funds|||||~788391|314378|~452013|53 100| |Transfer of funds||||||107,887|(107,887)||| |Fund balances|brought|forward||at|||||| |31 March 2022||||||3066436|107667|3 176325|3 123225| |Fund balances carried
at 31 March 2023||forward||||~4QL934|'~ZB|~2~|3 176325| ## |||||Notes|2023|2022f| |---|---|---|---|---|---|---| |FIXEDASSETS||||||| |Property
and equipment||||10|922,525|943,021| |Fixed term deposits||||||| ||||||922,525|943,021| |CURRENT ASSETS||||||| |Debtors||||11|976,313|452,574| |Fixed term deposits
Cash at bank and
in hand||||12|1610178|515,000
1653379| ||||||2,586,491|2,620,953| |CREDITORS: Amounts||due within one year||13|~784704|~367649| |NET CURRENT ASSETS|||||1 801 787|2251 177| |CREDITORS: Amounts||due after one year||||| |NET ASSETS|||||~~312|3 176325| |FUNDS OF THE|CHARITY|||||| |RESTRICTED|||||314,378|107,887| |UNRESTRICTED||||||| |Designated
funds||||||| |Property|||||922,525|943,021| |Support and|working||capital||119,361|116,924| |Grants|||||1,167,545|1,664,729| |General funds|||||200 503|343 764| |TOTAL FUNDS||||15|~2~|3 176325| ## |||||||2023|2022| |---|---|---|---|---|---|---|---| |Cash flows from operating
activities:|||||||| |Net cash provided
by operating
activities|||||(4)|~571537)|~38244| |Cash flows from investing
activities:|||||||| |Dividends,
interest and rents from investments||||||13,336|14,962| |Proceeds from sale of investments
Management
fees for short term deposits||||||1,975
~1975)|1,931
~1931| |Net cash from investing
activities||||||13336|14962| |Change
in cash and cash equivalents|in the||reporting|period||~558201)|21282| |Cash and cash equivalents
at the beginning||of|the reporting||||| |period||||||2168379|2 189661| |Cash and cash equivalents
at the end|ofthe||reporting|period||~~8|2 168379| |Where cash and cash equivalents
consists|of:||||||| |Cash at bank and
in hand|||||12|823,536|1,045,808| |Fixed term deposits
(current and non-current)||||||786 642|1 122571| |Cash and cash equivalents||||||~1QJ28|2 168 379| |(a) Reconciliation
of net expenditure
to net|cash||flows from|operating|activities||| |Net income for the reporting
period||||||(452,013)|53,100| |Adjustment
for:|||||||| |Depreciation
charge||||||20,496|20,496| |Dividends
and interest
from investments||||||(13,336)|(14,962)| |(Increase)/ Decrease
in debtors||||||(523,739)|(100,384)| |Increase/(Decrease)
in creditors||||||397055|5506| |Net cash provided
by/ (used in) by operating|||activities||||36244| ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## |nations|an|d Legacies|—Current year|||| |---|---|---|---|---|---|---| |||||Unrestricted|Restricted|Total| |||||Funds|Funds|2023| |Donations,||fundraising|and|||P| |legacies||||||| |Committed||giving||1,082,077|1,164,925|2,247,002| |Legacies|and bequests|||740 608||740 608| |nations|and Legacies||—Comparative|||| |||||Unrestricted|Restricted|Total| |Donations,||fundraising|and legacies|Funds|Funds|2022f| |Committed||giving||1,644,843|468,125|2,112,968| |Legacies|and bequests|||547891||547891| |||||2 192734|468 125|2660859| ## |ome from investments|—Current year|||| |---|---|---|---|---| |||Unrestricted|Restricted|Total| |||Funds|Funds|2023| |Interest on cash deposits||13336||13336| |ome from investments|—Comparative|||| |||Unrestricted|Restricted|Total| |||Funds|Funds|2022| |interest on cash deposits||14962||14962| |||14962||14962| ## ## ## ||||Unrestricted|Restricted|Total| |---|---|---|---|---|---| ||||Funds|Funds|2023| |Fundraising|costs||446,146||446,146| |Employment|costs|(see note 9)|603 685||603685| |penditure
on raising funds —Comparative|||||| ||||Unrestricted|Restricted|Total| ||||Funds|Funds|2022| |Fundraising|costs||435,770||435,770| |Employment|costs|(see note 9)|443290||443290| |aritable
activities||—Current year|||| ||||Unrestricted|Restricted|Total| ||||Funds|Funds|2023| |Grant funding|of activities (see note 8)||622,851|850,547|1,473,398| |Employment|costs|(see note 9)|536,609||536,609| |Project Management/EPPC|||157,137||157,137| |Support costs (see||note 7)|237838||237838| |Total expenditure||on charitable|||| |activities|||||| |haritable
activities
—Comparative|||| |---|---|---|---| ||Unrestricted|Restricted|Total| ||Funds|Funds|2022| |Grant funding
ofactivities (see note 8)|797,918|360,238|1,158,156| |Employment
costs (see note 9)|394,036||394,036| |Project Management7'EPPC|18,796||18,796| |Support costs (see note 7)|172673||172673| |Total expenditure
on charitable|||| |activities|1363423|360238|1 743661| ## ## |Support costs are allocated on|Support costs are allocated on|the basis||of staff|of staff|of staff|time and|time and|comprising
the following:|comprising
the following:| |---|---|---|---|---|---|---|---|---|---|---| ||||||||||2023|2022| |Other stationery
and postage|||||||||10,666|2,576| |Communication
expenses|||||||||50,936|32,179| |Booklets|||||||||20,374|11,681| |Office rent|||||||||17,371|6,146| |IT, phone and internet costs|||||||||48,006|39,199| |Recruitment|||||||||741|711| |Bank charges|||||||||4,277|4,417| |Memberships|||||||||15,527|9,276| |Sundry and office maintenance|||||||||12,056|11,288| |Depreciation|||||||||20,496|20,496| |Governance
costs||||||||||| |Auditor's
remuneration:||||||||||| |current year|||||||||19,988|14,874| |Trustee meeting expenses||||||||||| |Legal and professional|fees||||||||17400|18830| |Total||||||||||172673| |Grant funding
activities||||||||||| |Name of institution||Research||Grants|||||Total|Total| ||||||||||2023|2022f| |King's College London||Immunotherapy|||||||4,292|137,342| |||PlexinB1|||||||126,858|133,871| |||Wnt Signalling||||||||79,570| |Cardiff University||Bone mets/Targeting||||||Wnt||| |||Signalling|||||||148,432|52,397| |Cambridge
University||PTEN and||TSGs|||||144,117|86,431| |||ProCASP|||||||47,935|48,784| |Aberdeen
University||SoloMERS|||||||98,169|121,984| |Francis Crick institute||Machine|learning|||models|||51,220|39,808| |Oxford University||177Lu-PSMA|||||||117,012|113,232| |Newcastle
University||AR-V Splicing|||||||77,582|111,523| |||Glycan drugs|||targeting|||bone|134,179|43,880| |||metastasis||||||||| |University
of East Anglia||Al/Mathematical||||Classification|||115,699|69,912| |UCL||STAMPEDE|||||||90,921|12,152| |Cancer Research
UK||Targeting||MCL-1|||||52,350|22,183| |Imperial College London||Obesity and Prostate||||||Cancer|145,882|33,743| |University
of Sunderland||Disparities/Barriers|||||to|early|31,056|| |||diagnosis||||||||| |University
of Essex||Disparities/AR|||risk||||21,683|| |Other Grants costs||Research||grants|||||66011|51344| ||||||||||~~66|1 158 158| ## ## ||||||2023|2022| |---|---|---|---|---|---|---| |Charitable||activities|||10|| |Fundraising|||and marketing||14|| |Total||||||17| |The aggregate|||payroll costs ofthese persons were as follows:|||| ||||||2023|2022| |Salaries|and||wages||972,355|729,949| |Pensions|||||34,392|25,474| |National|Insurance||||105,058|67,607| |Training|and||recruitment||28489|14296| |Total|||||~L4L2R4|637326| |The number||of employees||whose salary exceeded F60,000was:||| ||||||2023|2022| ||||||No.|No.| ## ## ## ## |Debtors|||| |---|---|---|---| |Debtors due within one|year||| |||2023|2022| |Donations
Receivable|||| |Other debtors||515,868|251,852| |Amount
due from related|entity|317,192|140,508| |Prepayments||98625|56544| |||~~88|449204| ## ||Debtors more than one year||| |---|---|---|---| |||2023|2022| ||Prepayments|~28|3370| |12.|Cash and cash equivalents||| |||2023|2022| ||Cash|823,536|1,045,808| ||Fixed term deposits|786 642
~~8|607571
1653379| ## ## |reditors|—amounts
falling due within one y|ear|| |---|---|---|---| |||2023|2022| |Creditors|Control Account|143,453|103,700| |Accruals||472,287|241,716| |Deferred|Income|158,676|34,041| |Other creditors||10288|8 192| |||~84+I|387649| ## |t 31 March 2023|the charity
had received donatio|ns
specifically
for future funding
e|vents.| |---|---|---|---| |||2023|2022| |Balance brought
Movement
in the|forward
year|34,041
124835|104,804
~70 763| |At 31 March 2023|||34041| ## |Net (debt)/cash|-|current|year|||| |---|---|---|---|---|---|---| |||||At 1 April|Cash flow|At 31 March| |||||2022||2023| |Cash at bank and|in hand|||1,045,808|(222,272)|823,536| |Fixed term deposits||included|in cash equivalents|607,571|179,071|786,642| |Fixed term deposits
Fixed term current||(current|8 fixed assets)|515000|~515000)|| |Net (debt)/cash||||2 168379|~558 201)|~1QJ28| |Net (debt)/cash|-comparative|||||| |||||At 1 April|Cash flow|At31March| |||||2021||2022| |Cash at bank and|in hand|||1,343,434|(297,626)|1,045,808| |Fixed term deposits||included|in cash equivalents|251,227|356,344|607,571| |Fixed term deposits||(current|& fixed assets)|260,000|(260,000)|| |Fixed term current||||335000|180000|515000| |Net (debt)7'cash||||2 189661|~21282|2 168379| ## ## |nalysis of net assets between f|unds —current year||| |---|---|---|---| ||Unrestricted|Restricted|Total| ||||funds| |Fixed assets|922,525||922,525| |Fixed term Investments|||| |Debtors|976,313||976,313| |Cash and cash equivalents|1,295,800|314,378|1,610,178| |Creditors|~784704||~784 704| |Net assets at the end of year|~LGL934|'~zB|~2K~| |nalysis of net assets between f|unds —comparative||| |---|---|---|---| ||Unrestricted|Restricted|Total| ||||funds| |Fixed assets|943,021||943,021| |Fixed term Investments|515,000||515,000| |Debtors|452,574||452,574| |Cash and cash equivalents
Creditors|1,545,492
~387649|107,887|1,653,379
~387649| |Net assets at the end of year|3068438|107887|3176325| ||||||||||||||||||||'0 C
~C
0)O-
Ql
CL|||a$ 0|Ql
Ql|| |---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---| ||||||||||||||||||||Ql|||N||| ||||||||||||||||||||Ql .=|||N|0|| ||||||||||||||||||cd||cd ~|||||| ||||||||||||||||||||||||CD|| ||||||||||||||||||O||(d
Ql||||a$|| |||V
c
~|CV|4l||(A
(0
C)
Ccl||COw
'ct (0
(O (9
t
Cll
COr
~ w
1||CA
CV
(A
N
CCl
Cb|1
Cb
CV
CCI|ct
Cll
Ol
CI
CV|||||Ql
0
0|cl|cn
Ql
Q O
cd
CL
0 X
Ql|||0)
cdC
0&
N0)
0|0)
(d
0
Ql|| ||||(h
e
(h
(4|Ccl||(O
O||CV
(O
Cb|'ct
CV||CA
(O
00
($)|CO
QO
1|CO
CO
Cl
1||||&z
C
Ql
'
Ql
0
(n ~||Ql
cd
cd
0
(n
Ql~
8 C
cd~
(n .~|||C
U)
C
0)|QlO0)
Ql
E0
O|| |CV
z o
Z
LLI
eu
o&z
&
LLI o
I-
gJ
CO|||L-
'D
Ql
(h
4$$—4I
0 L
4l
'D
8
O.
LLI|||Ol
C)||00
($$ t
ct|'|cO
($$ct
O
CV||(O(0
CV
(0
CV||||Vl
cd
0$ Ql
0
0|Ql
a$ M
(n
0$ 8
Q
0$ C K
cd~
0)
Ql
0)~
cd ~
a$ O
E
(n8
Q) '~
O
a$ 0~C
cd||Ql
h~
P 8
QlC
(d~
O
cn
N
&
0$ Ql
0)
Ql
a$ 0)0
V)
0$ 0|||OC
Vl0)
E0
0)
cd
E
C
0)
0)
V)
(($ Vl
cd|0)
OC
Ul
(D
(D
0
a$ Ql
0)
1D
Ql|| ||||||||||||||||||Ql|(nC0|Ql
N0
8 0|||U)|0)
O
(D|| |moO
oz~
zc~
czz
OL-~K
z
LLI
u)Om
OI-Z
K 0 I-
0.
LLII-
z ~||Q.
~|cq
Cl
Cq
Ql
0V|||(A
00
1||I|I|I||||||Ql
Ql'p
cd
cd
Ql
Ql
Ql
a$ cd
Vl
(0
0$ QlO
cd|1
C
0
cd
E
'c
0
Ql
(n
O
(n|0$ (D
0
0)
0
0
8
K
0)
cdC
(D0
(n
0&
a$ 1D
cd
~|0)
Ql
CL
l
a$~
0~
Ql
N
(n
cd
c
cd
C
Ql
Ql
(d0»
N ~
N
(D
N
0«
cd
0)N+
(n
2
~
8
(($ o
Vl
Ql .~
0) & O
Ql
s 8
0 8
O»
Vl|||C
0)
0
0)
(n
0)
C0
NC0
OC
N
CD
0)
N0
CL
E
N
0$|0)
E0
O
(D
O
i
V)
0&
0)
CL
N
0)
0
cd
U
Ql
N
'p
cd|| ||8
C
4l
O
I
N
'O
C
LL||||N
'O
C
Ll
'ZJ
V
Ql
C
D|a$ 8
6|(II
'Dc
Ll
Ql
(4
Ul
O|N
~
G|cd
CL
cdO
0)
C
0
cd
0
CL
CL
CD|CL
0
s
Cl||cn
0)
O
N
Ql
a$0
I—|N
'D
C
LL
V
(h8
II|cn
C
0
I—|N
C
v
Ql
cd
«5
CI|0
Qlg
cn
cd
Ql
Ul
Vl
C
N
C8
Vl
Ql
h.8
V)
~
G|0)
(n
Ql
cd &
0.8
O—
cd
Ql
0
cn
QlN
cd
Ql
0 8
0. W
CD
I—CL||(n
Ql
+
cn c Q
(D
cd ~
a-
s
C
0&0
Q) C
0~ 0)
8 C .CCC
'0 0
a
cd»
(d
cd M
8
0
C~'O
0)
Ql C8
(n
cd 0
cd
Ql
C
(n g 8
(d 8~
CD
0 &||(h~
C
LL
'D
4l
(h
Ql
K|0C0
0)
Ql
0)
0)
(n
1D
~
CD
O
Vl
0)
K|i0
(D
1
a$O
V)
Ql
O
(n
(D
~
0
Ql|~
0)
Vl
C
O.
QlX| ## ## ## ## ## ||||||Total| |---|---|---|---|---|---| ||||Unrestricted|Restricted|funds| ||||funds|funds|2022| |Income and endowments||from:|||| |Donations
and|legacies||2,192,734|468,125|2,660,859| |Investments|||14,962||14,962| |Other income|||||| |Total income|||2207666|468 125|2675821| |Expenditure
on:|||||| |Raising funds|||879,060||879,060| |Charitable
activities|||1383423|360238|1 743661| |Total expenditure|||2262483|360238|2622 721| |Net movement|in funds||~54 787|107887|53 100| |Transfer offunds|||16,110|(16,110)|| |Fund balances|brought|forward at|||| |31March 2021|||3 107115|16 110|~~12 ~22| |Fund balances|carried forward||||| |at31March 2022|||3068438|107887|3176325|